A 56-year-old man presented to a peripheral hospital in New Zealand with severe Plasmodium falciparum malaria with cerebral involvement and subsequently developed multi-system organ failure. Activated protein C was used in an attempt to stop the cascade of events into multi-organ failure.
Malaria remains one of the major health issues in the world. Increases in worldwide travel have resulted in increased malarial infection in non-endemic areas 1 . Plasmodium falciparum is responsible for the most severe (life-threatening) forms of malaria and the progression from the prodromal stages though to multi-organ failure may occur in hours.
Despite advances in intensive care, the mortality of severe malaria remains approximately 20% in developed countries and may increase to 80% in cases with concurrent acute respiratory distress syndrome [2] [3] [4] .
The mainstay of treatment involves achieving therapeutic blood levels of the appropriate antimalarial agent along with supportive care. The development of an adjuvant therapy that could halt the progression to multi-organ failure may improve clinical outcomes.
CASE HISTORY
We report a 56-year-old mining engineer who had worked in Ghana for 10-week periods throughout the previous year, with the remainder of his time spent in New Zealand. He was advised to take anti-malarial prophylaxis by his General Practitioner.
His past medical history included previous malaria infection, type 2 diabetes mellitus, chronic atrial following recurrent ventricular tachycardia, an Five days after returning home from Ghana he pyrexia, headache and lethargy. He visited a general practitioner three times over the next week and a diagnosis of viral illness was made. On the night of admission he was found at home with confusion, shortness of breath and abdominal pain.
He was taken to a local cottage hospital where his initial recordings were as follows: temperature 40°C, BP 141/70, heart rate 101 bpm; a blood gas showed a pH of 7.58, PCO 2 24 mmHg, PO 2 HCO 3 22.7. He received ceftriaxone and gentamicin and was transferred to our hospital via private car.
On arrival in the emergency department he was in septic shock with a temperature of 40°C, blood pressure 78/45 mmHg (MAP=45), heart rate 110 bpm, bounding pulses and warm extremities. He remained confused and disorientated and had from 8 to 13/15. Examination did not reveal any localising signs except a diffusely tender abdomen. A computerised tomography scan of his head and abdomen demonstrated no abnormality. Two litres of department.
diagnosis of malarial infection was made and the patient was transferred to the intensive care unit (ICU).
with a mild to moderate load of Plasmodium falciparum. A diagnosis of malaria with cerebral involvement was An intravenous loading dose (2 mg/kg) of quinine sulphate 5, 6 was administered over four hours. 38/min), sweating profusely, hypotensive (systolic BP of 80 mmHg) and oliguric (urine output 35 ml on insertion of catheter and 17 ml over next four hours). Initial investigations indicated multi-organ involvement, including acute renal failure, thrombocytopenia, disordered coagulation (see Tables 1 and 2 ) and acute lung injury on chest X-ray, with saturations re-breathing mask. An ECG showed rapid atrial Arterial and central venous access was obtained, and a PiCCO system (Pulsion Medical Systems, Munich, Germany) inserted to monitor cardiac output. The initial cardiac index recording was 1.4 l/min/m 2 . were given. Noradrenaline (0.01-1.5 μg/kg/min), vasopressin (1-6 U/h) and adrenaline (0.2 to 0.5 μg/kg/min) were commenced and titrated to achieve a MAP of >65 mmHg and cardiac index of over 2 l/min/m 2 . A further three litres of crystalloid Approximately 15 minutes after intubation and ventilation he suffered a cardiac arrest that required two minutes of chest compressions and 1mg adrenaline boluses (total of 5 mg given). The inotrope and vasopressor infusions were increased to adrenaline 10 μg/kg/min, vasopressin 6 U/h, noradrenaline 1.5 μg/kg/min and 1 l of crystalloid and 1.5 l of colloid were given to achieve a central venous pressure of 15 mmHg. During this time he was paced at 60 bpm by his implanted pacemaker.
Due to escalating serum potassium (6.6 mml/l) he was commenced on continuous veno-venous A 2D echo performed after the circulatory arrest demonstrated severe biventricular failure with an ejection fraction of 22% and right heart systolic pressure of 60 mmHg. sites and had marked thrombocytopenia (platelets 10×10 /l) and impaired coagulation (INR 4.7, APTT 281s). Serial biochemistry and haematological values are shown in Tables 1 and 2 .
Over the next eight hours he demonstrated ongoing septic shock and multi-organ failure. He remained anuric, continued to require high doses of vasopressors and inotropes to achieve a MAP of His clinical condition met the New Zealand criteria for the use of activated protein C (Drotrecogin Alfa, recombinant human activated protein C, Xigris™, Eli Lilly & Co., New Zealand) 7 . The coagulopathy was treated with pooled platelets to achieve a platelet count of greater than 30×10 /l 7 and cryoprecipitate.
Following discussion with the family to explain his deterioration and the bleeding risks he was commenced on activated protein C at 24 μg/kg/hour platelet transfusions to maintain a platelet count above 30×10 /l. He showed rapid improvement over the next 12 hours such that adrenaline was weaned off within four hours and the vasopressors were able to be weaned down and subsequently ceased 14 hours after commencement of activated protein C. Following the completion of the infusion, he no longer required platelet transfusions and his coagulopathy improved. His renal function improved such that the His medication was converted to oral anti-malarial P. vivax, a two-week course of primaquine for His ICU stay was complicated by episodes of supraventricular tachycardia terminated with adenosine. He remained ventilator dependent for a prolonged period (16 days) due to a Pseudomonas aeruginosa pneumonia that developed on day 10.
He was gradually weaned off sedation and was extubated on day 16. improvement in systolic function with ejection fraction 50% and right heart pressures of 36 mmHg. He was discharged to the ward on day 18 and after a period in the rehabilitation unit went home on day 25 having made a full recovery.
DISCUSSION
Approximately 40% of the world's population is at risk of malaria. It is estimated to cause 300 million acute infections and approximately 1.1 million deaths annually 8 .
There are four types of human malaria, the most common being P. falciparum and P. vivax. P. falciparum carries the highest mortality as it may rapidly evolve into life-threatening multi-system disease 5, 3 .
Increases in worldwide travel and immigration have meant that malaria is becoming more common in developed countries 2 . Approximately 16,000 diagnoses are made annually in Europe and 1,300 new cases per year in the United States . It is still relatively uncommon in New Zealand; 32 new population) 10 .
Mortality has remained high over the last 20 years. The current mainstay of treatment has been antimalarial agents 5, 6 and symptomatic relief. Various new therapeutic approaches including dexamethasone, hyperimmune IgG, desferrioxamine, anti-tumour necrosis factor-alpha monoclonal antibodies and exchange transfusion have been trialled. None has been shown to be clearly effective . similar to that found in other severe infections, is seen and leads to generalised septic shock 11 . This includes acidosis, increased vascular permeability, pathological vasodilatation and sequestration of parasitised erythrocytes in the microvasculature of vital organs and a pro-coagulant state 12, 13 .
To date there has been no successful method of preventing multi-organ failure from malaria 13, 14 .
response syndrome (SIRS) caused by severe malaria is not fully understood. It was previously accepted that sequestration of parasitised erythrocytes was the primary cause of microvascular obstruction and hypoxia leading to multi-organ failure 4 . More recent studies 12, 15, 16 have indicated that the excess that of bacterial sepsis alters the balance between areas of hypoperfusion, tissue necrosis and development of multi-organ dysfunction 15, 17 .
Elevated tumour necrosis factor alpha (TNF ), thrombin-antithrombin III levels and decreased plasma levels of anticoagulant protein C have been measured in patients with P. falciparum and indicate a shift in the balance of haemostatic activity towards a procoagulant state 16, 18 .
In severe P. falciparum serum TNF is elevated and protein C activity depressed, especially in those patients with complications. The reduction in protein P=0.001) with greater parasitaemia and higher TNF and are reversed during anti-parasitic treatment 12 .
High levels of thrombin-antithrombin complexes and activation of the coagulation cascade lead to higher use and thus depletion of coagulation inhibitors.
The low activity of coagulation inhibitors in severe malaria is important, not only due to their regulatory role in the coagulation cascade but also because of 14 .
The development of severe malaria is comparable with severe sepsis syndrome and thus new adjuvant malaria treatment may be envisaged 14 . The relationship between severe sepsis and a hypercoagulable state leading ultimately to disseminated intravascular coagulation and multi-organ failure is well established . Recombinant human activated protein C has been used in its treatment 7, 14, 15 .
The administration of activated protein C and antithrombin III during sepsis has been shown to stabilise the coagulation cascade and improves the signs and symptoms of the disease and reduces mortality rates . The activation of protein C may be a control mechanism related to host defense in both sepsis and malaria. This hypothesis is supported by data indicating a correlation between low protein C levels and the more severe clinical course of malaria 12 .
protein C exerts its effects on survival is not completely understood 15 . The anti-thrombotic and thrombus formation, thereby diminishing ischaemic . Unfortunately these effects also increase the risk of serious bleeding complications including intracranial haemorrhage . In this patient we corrected the thrombocytopenia with platelet transfusions prior to infusing activated protein C.
Although the initiating pathway may be different from those of gram positive or gram negative infections, the presence of SIRS with malarial sepsis if there is organ dysfunction).
In this patient, disordered coagulation and thrombocytopenia was noted with his initial blood tests (Table 1 ) and progressively deteriorated with his rapidly (day 2) which may have been due to the activated protein C.
Activated protein C may be considered for use in severe malaria to halt the cascade that leads to the development of multi-organ failure. Further study is required to evaluate the effectiveness and the riskmalarial patients who have life-threatening illness.
